Bafna Pharmaceuticals Limited Total Liabilities
Bafna Pharmaceuticals Limited total liabilities. Based on the latest financial reports, Bafna Pharmaceuticals Limited (BAFNAPH) has total liabilities worth Rs753.88 Million INR (≈ $8.15 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BAFNAPH cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Bafna Pharmaceuticals Limited (2005–2026)
Total liabilities of Bafna Pharmaceuticals Limited from 2005 to 2026. This chart illustrates how Bafna Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data.
Bafna Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of Bafna Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Atomera Inc
NASDAQ:ATOM
|
USA | $2.71 Million |
|
Answear.com S.A.
WAR:ANR
|
Poland | zł628.64 Million |
|
STIF Société anonyme
PA:ALSTI
|
France | €24.97 Million |
|
Apiam Animal Health Ltd
AU:AHX
|
Australia | AU$134.72 Million |
|
Kulmbacher Brauerei Aktien-Gesellschaft
MU:KUL
|
Germany | €168.79 Million |
|
Gabelli Global Utility & Income Tr
NYSE MKT:GLU
|
USA | $291.78K |
|
Cashbil
JSE:CSB
|
South Africa | ZAC5.34 Billion |
|
INNATE PHARMA SP.ADR/1
F:IDDA
|
Germany | €84.42 Million |
Liability Composition Analysis (2005–2026)
This chart breaks down Bafna Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Bafna Pharmaceuticals Limited balance sheet assets.
Liquidity & Leverage Metrics
Bafna Pharmaceuticals Limited Total Liabilities Ratios Explained
Bafna Pharmaceuticals Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bafna Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bafna Pharmaceuticals Limited (2005–2026)
The table below shows the annual total liabilities of Bafna Pharmaceuticals Limited from 2005 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs753.88 Million ≈ $8.15 Million |
+10.42% |
| 2025-03-31 | Rs682.73 Million ≈ $7.38 Million |
+2.14% |
| 2024-03-31 | Rs668.43 Million ≈ $7.23 Million |
+19.09% |
| 2023-03-31 | Rs561.29 Million ≈ $6.07 Million |
+99.17% |
| 2022-03-31 | Rs281.81 Million ≈ $3.05 Million |
-5.10% |
| 2021-03-31 | Rs296.95 Million ≈ $3.21 Million |
+47.61% |
| 2020-03-31 | Rs201.17 Million ≈ $2.18 Million |
-80.01% |
| 2019-03-31 | Rs1.01 Billion ≈ $10.88 Million |
-0.53% |
| 2018-03-31 | Rs1.01 Billion ≈ $10.94 Million |
-25.72% |
| 2017-03-31 | Rs1.36 Billion ≈ $14.73 Million |
+0.92% |
| 2016-03-31 | Rs1.35 Billion ≈ $14.59 Million |
+6.17% |
| 2015-03-31 | Rs1.27 Billion ≈ $13.75 Million |
-23.46% |
| 2014-03-31 | Rs1.66 Billion ≈ $17.96 Million |
-13.63% |
| 2013-03-31 | Rs1.92 Billion ≈ $20.79 Million |
+24.60% |
| 2012-03-31 | Rs1.54 Billion ≈ $16.69 Million |
+89.51% |
| 2011-03-31 | Rs814.33 Million ≈ $8.81 Million |
+88.84% |
| 2010-03-31 | Rs431.23 Million ≈ $4.66 Million |
+9.71% |
| 2009-03-31 | Rs393.06 Million ≈ $4.25 Million |
+0.09% |
| 2008-03-31 | Rs392.72 Million ≈ $4.25 Million |
-12.47% |
| 2007-03-31 | Rs448.70 Million ≈ $4.85 Million |
+184.28% |
| 2006-03-31 | Rs157.84 Million ≈ $1.71 Million |
+25.31% |
| 2005-03-31 | Rs125.96 Million ≈ $1.36 Million |
-- |
About Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences … Read more